Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16722737 | 0.73 | NOS1 (0.39) | EGFRLPLLIPG | |
| SCHEMBL2379179 | 0.73 | LPL (0.40) | EGFRLPLLIPGMAPT | |
| SCHEMBL18239676 | 0.73 | GSK3A (0.39) | EGFRLPLLIPG | |
| SCHEMBL16728679 | 0.72 | EGFR (0.35) | EGFRLPLLIPG | |
| SCHEMBL982572 | 0.72 | AHR (0.39) | EGFRLPLLIPG | |
| SCHEMBL4789211 | 0.71 | LPL (0.42) | EGFRLPLLIPG | |
| SCHEMBL2204718 | 0.70 | LPL (0.41) | EGFRLPLLIPG | |
| SCHEMBL874992 | 0.70 | MMP12 (0.45) | EGFRLPLLIPGMAPT | |
| SCHEMBL29525463 | 0.70 | MMP12 (0.45) | EGFRLPLLIPGMAPT | |
| SCHEMBL18572048 | 0.70 | EGFR (0.40) | EGFRLPLLIPGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3654978-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | Nuvation Bio Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019018584-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | GiraFpharma LLC (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | EGFR 2241/4885LPL 4723/4885LIPG 4081/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | EGFR 2241/4885LPL 4723/4885LIPG 4081/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | EGFR 2241/4885LPL 4723/4885LIPG 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.